Scinai Immunotherapeutics LT
13F holders, Q3 2024 (September 30)5holders −4
0new positions
4sold out
$3.52avg. 13F price*
At the end of Q3 2024, 5 institutions reported holding Scinai Immunotherapeutics LT in their 13F filings, down 4 from Q2 2024. 0 opened new positions and 4 sold out. The largest holders were Rhumbline Advisers ($6K), Morgan Stanley ($880) and Credit Agricole S A ($145).
- Company
- Scinai Immunotherapeutics LT
- Filed as
- BIONDVAX PHARMACEUTICALS LTD (Q3 2024)
- CUSIP
- 09073Q303
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 4 | $50K |
All 13F filers, Q2 2024 → Q3 2024: 515 shares bought and 18,134 shares sold, net −17,619 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Rhumbline Advisers | 0.00% | Add +45.3% | 1,653 | $6K |
| Morgan Stanley | 0.00% | No change | 255 | $880 |
| Credit Agricole S A | 0.00% | No change | 42 | $145 |
| Aspire Private Capital, LLC | 0.00% | No change | 32 | $110 |
| UBS Group AG | 0.00% | Reduce -85.8% | 30 | $104 |
"% of holder's portfolio" is SCINAI IMMUNOTHERAPEUTICS LT's weight in each manager's 13F, not the share of Scinai Immunotherapeutics LT the manager owns.